<p>世界投资顾问在第四季度购买了 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的新股份，根据该公司最近向美国证券交易委员会提交的 13F 表格。该基金购买了 16,290 股公司股票，价值约为 1,664,000 美元。</p>
<ul>
<li>4 只医疗保健股票大幅上涨——未来还有更多机会</li>
</ul>
<p>其他几家大型投资者也对 GH 的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Guardant Health 的股份增加了 56.5%。AQR Capital Management LLC 目前拥有 71,534 股公司股票，价值 3,012,000 美元，此前在上个季度又购买了 25,831 股。Empowered Funds LLC 在第一季度购买了价值约 274,000 美元的 Guardant Health 新股份。Sei Investments Co. 在第二季度将其在 Guardant Health 的持股增加了 15.8%。Sei Investments Co. 目前拥有 77,308 股公司股票，价值 4,023,000 美元，此前在上个季度又购买了 10,538 股。制造商人寿保险公司在第二季度将其在 Guardant Health 的持股增加了 9.4%。制造商人寿保险公司目前拥有 632,630 股公司股票，价值 32,922,000 美元，此前在上个季度又购买了 54,284 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度将其在 Guardant Health 的持股增加了 56.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 111,445 股公司股票，价值 5,800,000 美元，此前在上个季度又购买了 40,209 股。机构投资者目前持有公司 92.60% 的股份。</p>
<p>获取 <strong>Guardant Health</strong> 警报：</p>
<h2>Guardant Health 股价下跌 3.8%</h2>
<p>NASDAQ GH 的股票周五开盘价为 94.92 美元。该公司的 50 日简单移动平均线为 89.30 美元，200 日简单移动平均线为 97.90 美元。该公司的市值为 125.9 亿美元，市盈率为 -28.00，贝塔值为 1.48。Guardant Health, Inc. 的一年最低价为 36.36 美元，一年最高价为 120.74 美元。</p>
<ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
<p>Guardant Health (NASDAQ:GH - 获取免费报告) 最近在 2 月 19 日星期四发布了其财报。公司报告本季度每股收益为 ($0.50)，低于分析师一致预期的 ($0.43) 0.07 美元。公司本季度的收入为 2.8127 亿美元，而分析师预期为 2.6974 亿美元。与去年同期相比，公司季度收入增长了 39.4%。去年同期，该公司每股收益为 ($0.62)。研究分析师平均预计 Guardant Health, Inc. 本财年的每股收益将为 -2.87。</p>
<h2>分析师设定新目标价</h2>
<p>GH 已成为几份分析师报告的主题。Raymond James Financial 在 2 月 23 日的报告中重申了 “跑赢大盘” 的评级，并对 Guardant Health 的股票设定了 129.00 美元的目标价。Leerink Partners 将 Guardant Health 的目标价从 170.00 美元上调至 180.00 美元，并在 2 月 20 日的报告中给予该股票 “跑赢大盘” 的评级。Barclays 将 Guardant Health 的目标价从 115.00 美元上调至 120.00 美元，并在 5 月 8 日的报告中给予该股票 “增持” 的评级。瑞银集团在 1 月 30 日的报告中重申了 “买入” 评级，并对 Guardant Health 的股票设定了 175.00 美元的目标价。最后，Weiss Ratings 在 4 月 21 日的报告中重申了对 Guardant Health 的 “卖出 (d-)” 评级。十九位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 129.42 美元。</p>
<ul>
<li>3 只快速增长的股票分析师预计价格翻倍</li>
</ul>
<p><strong>获取我们对 GH 的最新分析</strong></p>
<h2>内部人士下注</h2>
<p>在相关消息中，首席财务官 Michael Brian Bell 于 3 月 16 日星期一出售了 3,000 股公司股票。股票以平均价格 87.04 美元出售，总价值为 261,120.00 美元。交易完成后，首席财务官直接持有公司 43,601 股，价值约为 3,795,031.04 美元。这代表了他们持股比例的 6.44% 的减少。该出售在向 SEC 提交的文件中披露，文件可通过此超链接获取。此外，内部人士 Terilyn J. Monroe 于 4 月 6 日星期一出售了 3,832 股公司股票。股票以平均价格 92.68 美元出售，总价值为 355,149.76 美元。交易完成后，内部人士持有公司 20,990 股，价值 1,945,353.20 美元。此交易代表了他们持股比例的 15.44% 的减少。该出售的披露在 SEC 文件中可获得。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士共出售了价值 5,791,767 美元的 58,596 股公司股票。当前 5.60% 的股票由内部人士持有。</p>
<h2>Guardant Health 公司简介</h2>
<p>(免费报告)</p>
<p>Guardant Health, Inc 是一家专注于血液癌症诊断的精准肿瘤学公司。公司成立于 2012 年，总部位于加利福尼亚州红木城，开发非侵入性测试，利用循环肿瘤 DNA (ctDNA) 来分析实体肿瘤患者的基因组变化。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据来推动癌症护理的发展。</p>
<p>公司的旗舰产品 Guardant360 是一种下一代测序 (NGS) 检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变化和特定融合。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，而不是 Guardant Health</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师们喜爱的三家关键航空航天组件制造商</li>
<li>Alphabet 的 Googlebook 将 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在你考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>世界投资顾问公司在第四季度收购了 Guardant Health, Inc.（纳斯达克代码：GH）的新股份，购买了 16,290 股，价值约为 166 万美元。其他投资者，包括 AQR 资本管理公司和 Sei 投资公司，也增加了他们的持股。Guardant Health 的股票开盘价为 94.92 美元，市值为 125.9 亿美元。该公司报告的季度收入为 2.8127 亿美元，同比增长 39.4%，但未能达到每股收益的预期。分析师的评级各不相同，普遍目标价为 129.42 美元</p>

<p>World Investment Advisors purchased a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 16,290 shares of the company's stock, valued at approximately $1,664,000.</p>
<div class="lb-trans"><p>世界投资顾问在第四季度购买了 Guardant Health, Inc. (NASDAQ:GH - 免费报告) 的新股份，根据该公司最近向美国证券交易委员会提交的 13F 表格。该基金购买了 16,290 股公司股票，价值约为 1,664,000 美元。</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——未来还有更多机会</li>
</ul>
</div><p>Several other large investors have also made changes to their positions in GH. AQR Capital Management LLC grew its stake in shares of Guardant Health by 56.5% in the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company's stock valued at $3,012,000 after buying an additional 25,831 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Guardant Health in the 1st quarter valued at approximately $274,000. Sei Investments Co. lifted its holdings in Guardant Health by 15.8% in the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company's stock worth $4,023,000 after purchasing an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Guardant Health by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company's stock worth $32,922,000 after purchasing an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Guardant Health by 56.4% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company's stock worth $5,800,000 after purchasing an additional 40,209 shares during the last quarter. Institutional investors own 92.60% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者也对 GH 的持仓进行了调整。AQR Capital Management LLC 在第一季度将其在 Guardant Health 的股份增加了 56.5%。AQR Capital Management LLC 目前拥有 71,534 股公司股票，价值 3,012,000 美元，此前在上个季度又购买了 25,831 股。Empowered Funds LLC 在第一季度购买了价值约 274,000 美元的 Guardant Health 新股份。Sei Investments Co. 在第二季度将其在 Guardant Health 的持股增加了 15.8%。Sei Investments Co. 目前拥有 77,308 股公司股票，价值 4,023,000 美元，此前在上个季度又购买了 10,538 股。制造商人寿保险公司在第二季度将其在 Guardant Health 的持股增加了 9.4%。制造商人寿保险公司目前拥有 632,630 股公司股票，价值 32,922,000 美元，此前在上个季度又购买了 54,284 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度将其在 Guardant Health 的持股增加了 56.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 111,445 股公司股票，价值 5,800,000 美元，此前在上个季度又购买了 40,209 股。机构投资者目前持有公司 92.60% 的股份。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 警报：</p>
</div><h2>Guardant Health Trading Down 3.8%</h2>
<div class="lb-trans"><h2>Guardant Health 股价下跌 3.8%</h2>
</div><p>Shares of NASDAQ GH opened at $94.92 on Friday. The business has a fifty day simple moving average of $89.30 and a 200 day simple moving average of $97.90. The firm has a market capitalization of $12.59 billion, a price-to-earnings ratio of -28.00 and a beta of 1.48. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $120.74.</p>
<div class="lb-trans"><p>NASDAQ GH 的股票周五开盘价为 94.92 美元。该公司的 50 日简单移动平均线为 89.30 美元，200 日简单移动平均线为 97.90 美元。该公司的市值为 125.9 亿美元，市盈率为 -28.00，贝塔值为 1.48。Guardant Health, Inc. 的一年最低价为 36.36 美元，一年最高价为 120.74 美元。</p>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：深入了解 Cathie Wood 的最新投资</li>
</ul>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. The company's quarterly revenue was up 39.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.62) EPS. On average, research analysts anticipate that Guardant Health, Inc. will post -2.87 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health (NASDAQ:GH - 获取免费报告) 最近在 2 月 19 日星期四发布了其财报。公司报告本季度每股收益为 ($0.50)，低于分析师一致预期的 ($0.43) 0.07 美元。公司本季度的收入为 2.8127 亿美元，而分析师预期为 2.6974 亿美元。与去年同期相比，公司季度收入增长了 39.4%。去年同期，该公司每股收益为 ($0.62)。研究分析师平均预计 Guardant Health, Inc. 本财年的每股收益将为 -2.87。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>GH has been the subject of several analyst reports. Raymond James Financial restated an &#34;outperform&#34; rating and issued a $129.00 target price on shares of Guardant Health in a report on Monday, February 23rd. Leerink Partners boosted their target price on Guardant Health from $170.00 to $180.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, February 20th. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, May 8th. UBS Group restated a &#34;buy&#34; rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Guardant Health in a report on Tuesday, April 21st. Nineteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $129.42.</p>
<div class="lb-trans"><p>GH 已成为几份分析师报告的主题。Raymond James Financial 在 2 月 23 日的报告中重申了 “跑赢大盘” 的评级，并对 Guardant Health 的股票设定了 129.00 美元的目标价。Leerink Partners 将 Guardant Health 的目标价从 170.00 美元上调至 180.00 美元，并在 2 月 20 日的报告中给予该股票 “跑赢大盘” 的评级。Barclays 将 Guardant Health 的目标价从 115.00 美元上调至 120.00 美元，并在 5 月 8 日的报告中给予该股票 “增持” 的评级。瑞银集团在 1 月 30 日的报告中重申了 “买入” 评级，并对 Guardant Health 的股票设定了 175.00 美元的目标价。最后，Weiss Ratings 在 4 月 21 日的报告中重申了对 Guardant Health 的 “卖出 (d-)” 评级。十九位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 129.42 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师预计价格翻倍</li>
</ul>
</div><p><strong>Get Our Latest Analysis on GH</strong></p>
<div class="lb-trans"><p><strong>获取我们对 GH 的最新分析</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, CFO Michael Brian Bell sold 3,000 shares of the company's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $87.04, for a total value of $261,120.00. Following the completion of the transaction, the chief financial officer directly owned 43,601 shares in the company, valued at approximately $3,795,031.04. This represents a 6.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Terilyn J. Monroe sold 3,832 shares of the company's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $92.68, for a total value of $355,149.76. Following the completion of the sale, the insider owned 20,990 shares in the company, valued at $1,945,353.20. This trade represents a 15.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 58,596 shares of company stock valued at $5,791,767 in the last ninety days. 5.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Michael Brian Bell 于 3 月 16 日星期一出售了 3,000 股公司股票。股票以平均价格 87.04 美元出售，总价值为 261,120.00 美元。交易完成后，首席财务官直接持有公司 43,601 股，价值约为 3,795,031.04 美元。这代表了他们持股比例的 6.44% 的减少。该出售在向 SEC 提交的文件中披露，文件可通过此超链接获取。此外，内部人士 Terilyn J. Monroe 于 4 月 6 日星期一出售了 3,832 股公司股票。股票以平均价格 92.68 美元出售，总价值为 355,149.76 美元。交易完成后，内部人士持有公司 20,990 股，价值 1,945,353.20 美元。此交易代表了他们持股比例的 15.44% 的减少。该出售的披露在 SEC 文件中可获得。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士共出售了价值 5,791,767 美元的 58,596 股公司股票。当前 5.60% 的股票由内部人士持有。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家专注于血液癌症诊断的精准肿瘤学公司。公司成立于 2012 年，总部位于加利福尼亚州红木城，开发非侵入性测试，利用循环肿瘤 DNA (ctDNA) 来分析实体肿瘤患者的基因组变化。Guardant Health 的使命是通过向全球临床医生、制药合作伙伴和研究人员提供可操作的数据来推动癌症护理的发展。</p>
</div><p>The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.</p>
<div class="lb-trans"><p>公司的旗舰产品 Guardant360 是一种下一代测序 (NGS) 检测，旨在检测 70 多种与癌症相关的基因中的突变、拷贝数变化和特定融合。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>3 Stocks to Own If Gas Prices Keep Rising</li>
<li>3 Crucial Aerospace Component Makers That Analysts Love</li>
<li>Alphabet's Googlebook Brings Gemini AI to PC Hardware</li>
<li>Peloton Stock Gives Back Gains After Upbeat Earnings Report</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Guardant Health</li>
<li>如果油价持续上涨，值得拥有的三只股票</li>
<li>分析师们喜爱的三家关键航空航天组件制造商</li>
<li>Alphabet 的 Googlebook 将 Gemini AI 引入 PC 硬件</li>
<li>Peloton 股票在乐观的财报发布后回吐涨幅</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH

Market Beat

Guardant Health

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

基因免疫&健康关怀 ETF - iShares

美国医疗保健供应商 ETF - iShares

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - SPDR

医药突破 ETF - ALPS

美国医药设备 ETF - iShares

SEI投资

宏利金融

瑞杰金融

巴克莱银行

瑞银集团

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

世界投资顾问公司购入了 Guardant Health, Inc. $GH 的新头寸